[{"address1": "12770 High Bluff Drive", "address2": "Suite 150", "city": "San Diego", "state": "CA", "zip": "92130", "country": "United States", "phone": "619 949 3681", "website": "https://www.gyretx.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Gyre Therapeutics, Inc., a pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis. It offers ETUARY (Pirfenidone), an anti-fibrotic drug approved for the treatment of idiopathic pulmonary fibrosis; and under phase 3 studies for dermatomyositis and systemic sclerosis-associated interstitial lung disease, pneumoconiosis, and diabetic kidney disease. The company is also involved the development of F351 (Hydronidone), a structural derivative of ETUARY (Pirfenidone), under Phase 3 studies for the treatment of chronic hepatitis B liver fibrosis; and under Phase 1 studies for liver fibrosis associated with nonalcoholic associated steatohepatitis. In addition, its development pipeline includes F573, under Phase 2 studies for the treatment of acute/acute-on-chronic liver failure; F528, under preclinical stage for the treatment of chronic obstructive pulmonary disease; and F230, under preclinical stage for the treatment of pulmonary arterial hypertension. The company was founded in 2002 and is headquartered in San Diego, California. Gyre Therapeutics, Inc. operates as a subsidiary of GNI USA, Inc.", "fullTimeEmployees": 593, "companyOfficers": [{"maxAge": 1, "name": "Mr. Songjiang  Ma", "age": 68, "title": "President & Chairman", "yearBorn": 1956, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Han  Ying Ph.D.", "age": 58, "title": "CEO & Director", "yearBorn": 1966, "fiscalYear": 2023, "totalPay": 10500, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Ruoyu  Chen", "age": 53, "title": "Chief Financial Officer", "yearBorn": 1971, "fiscalYear": 2023, "totalPay": 121352, "exercisedValue": 0, "unexercisedValue": 15073756}, {"maxAge": 1, "name": "Mr. Weiguo  Ye", "age": 46, "title": "Chief Operating Officer", "yearBorn": 1978, "fiscalYear": 2023, "totalPay": 274617, "exercisedValue": 0, "unexercisedValue": 41527968}, {"maxAge": 1, "name": "Ms. Seline E. Miller CPA", "age": 54, "title": "Senior Vice President of Finance", "yearBorn": 1970, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 9, "boardRisk": 9, "compensationRisk": 9, "shareHolderRightsRisk": 7, "overallRisk": 9, "governanceEpochDate": 1740787200, "compensationAsOfEpochDate": 1703980800, "executiveTeam": [], "maxAge": 86400, "priceHint": 2, "previousClose": 11.96, "open": 11.92, "dayLow": 11.92, "dayHigh": 12.62, "regularMarketPreviousClose": 11.96, "regularMarketOpen": 11.92, "regularMarketDayLow": 11.92, "regularMarketDayHigh": 12.62, "payoutRatio": 0.0, "forwardPE": 26.326086, "volume": 92082, "regularMarketVolume": 92082, "averageVolume": 92233, "averageVolume10days": 116920, "averageDailyVolume10Day": 116920, "bid": 0.0, "ask": 0.0, "bidSize": 0, "askSize": 0, "marketCap": 1039308096, "fiftyTwoWeekLow": 8.26, "fiftyTwoWeekHigh": 19.0, "priceToSalesTrailing12Months": 9.895062, "fiftyDayAverage": 11.3134, "twoHundredDayAverage": 12.2212, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 1051305728, "profitMargins": -0.84566003, "floatShares": 16138878, "sharesOutstanding": 85822304, "sharesShort": 1346149, "sharesShortPriorMonth": 1248253, "sharesShortPreviousMonthDate": 1738281600, "dateShortInterest": 1740700800, "sharesPercentSharesOut": 0.015700001, "heldPercentInsiders": 0.74626, "heldPercentInstitutions": 0.01958, "shortRatio": 25.11, "shortPercentOfFloat": 0.2002, "impliedSharesOutstanding": 85822304, "bookValue": 0.737, "priceToBook": 16.431479, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1727654400, "earningsQuarterlyGrowth": -0.717, "netIncomeToCommon": -88822000, "trailingEps": -1.04, "forwardEps": 0.46, "lastSplitFactor": "1:15", "lastSplitDate": 1698710400, "enterpriseToRevenue": 10.009, "enterpriseToEbitda": 89.079, "52WeekChange": -0.3327824, "SandP52WeekChange": 0.09506309, "lastDividendValue": 3.6, "lastDividendDate": 1673568000, "quoteType": "EQUITY", "currentPrice": 12.11, "targetHighPrice": 20.0, "targetLowPrice": 20.0, "targetMeanPrice": 20.0, "targetMedianPrice": 20.0, "recommendationMean": 1.0, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 1, "totalCash": 25092000, "totalCashPerShare": 0.292, "ebitda": 11802000, "totalDebt": 1795000, "quickRatio": 3.111, "currentRatio": 3.724, "totalRevenue": 105033000, "debtToEquity": 1.823, "revenuePerShare": 1.285, "returnOnEquity": -0.85323995, "grossProfits": 101076000, "operatingCashflow": 2477000, "earningsGrowth": -0.738, "revenueGrowth": -0.205, "grossMargins": 0.96233004, "ebitdaMargins": 0.11236, "operatingMargins": 0.16608, "financialCurrency": "USD", "symbol": "GYRE", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "regularMarketChangePercent": 1.2541773, "regularMarketPrice": 12.11, "longName": "Gyre Therapeutics, Inc.", "marketState": "CLOSED", "corporateActions": [], "postMarketTime": 1741982710, "regularMarketTime": 1741982401, "exchange": "NCM", "messageBoardId": "finmb_100542295", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "fiftyTwoWeekChangePercent": -33.27824, "dividendDate": 1673481600, "earningsTimestamp": 1739885400, "earningsTimestampStart": 1742819400, "earningsTimestampEnd": 1743165000, "isEarningsDateEstimate": true, "epsTrailingTwelveMonths": -1.04, "epsForward": 0.46, "fiftyDayAverageChange": 0.7965994, "fiftyDayAverageChangePercent": 0.070412025, "twoHundredDayAverageChange": -0.11120033, "twoHundredDayAverageChangePercent": -0.00909897, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "averageAnalystRating": "1.0 - Strong Buy", "cryptoTradeable": false, "shortName": "Gyre Therapeutics, Inc.", "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1144848600000, "postMarketChangePercent": 0.0, "postMarketPrice": 12.11, "postMarketChange": 0.0, "regularMarketChange": 0.14999962, "regularMarketDayRange": "11.92 - 12.62", "fullExchangeName": "NasdaqCM", "averageDailyVolume3Month": 92233, "fiftyTwoWeekLowChange": 3.8499994, "fiftyTwoWeekLowChangePercent": 0.46610162, "fiftyTwoWeekRange": "8.26 - 19.0", "fiftyTwoWeekHighChange": -6.8900003, "fiftyTwoWeekHighChangePercent": -0.3626316, "displayName": "Gyre Therapeutics", "trailingPegRatio": null, "__fetch_time": "2025-03-15"}]